|
|
|
| Clinical efficacy comparison of different dose-intensity SOX in neoadjuvant chemotherapy for advanced gastric cancer |
| SHEN Xu′ning ZHU Yi PENG Yuping |
| Department of Gastrointestinal Surgery, the First Hospital of Jiaxing City, Zhejiang Province, Jiaxing 314000, China |
|
|
|
Abstract Objective To investigate the clinical efficacy of Oxaliplatin + SOX at different doses of chemotherapy in neoadjuvant chemotherapy for advanced gastric cancer. Methods From November 2011 to December 2016, 66 patients with advanced gastric cancer received neoadjuvant chemotherapy of SOX regimen in the Department of Gastrointestinal Surgery, the First Hospital of Jiaxing City were selected as the research subjects and divided into the standard dose intensity group (31 cases, Oxaliplatin:130 mg/m2, d1; SOX:60 mg/d, d1-14) and low dose group (35 cases, Oxaliplatin:104 mg/m2, d1; SOX:50 mg/d, d1-14) by draw method. The clinical efficacy, surgical conditions, adverse reactions to chemotherapy, survival time under the different doses of intensity SOX were analyzed. Results There were no statistically significant differences in the total clinical effective rate, the tumor control rate and R0 resection rate (all P ＞ 0.05). The incidences of thrombocytopenia and peripheral neurotoxicity in the standard dose intensity group were all significantly higher than those of low dose group, with statistically significant differences (all P ＜ 0.05). Follow-up was performed in 55 patients with gastric cancer underwent R0 resection. There were no statistically significant differences in 1 year and 3 years survival rate (all P ＞ 0.05). The median survival time in both groups was 33 months. Conclusion Compared with the standard dose intensity SOX regimen, the low dose SOX has the same efficacy and long-term efficacy for patients with gastric cancer requiring neoadjuvant chemotherapy and has greater safety.
|
|
|
|
|
|
[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2016. CA [J]. Cancer J Clin，2016，66（1）：7-30.
[2] Fu T，Bu ZD，Li ZY，et al. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma：a meta-analysis of randomized clinical trials [J]. BMC Cancer，2015，15（1）：322.
[3] Das M. Neoadjuvant chemotherapy：survival benefit in gastric cancer [J]. Lancet Oncol，2017，18（6）：e307.
[4] Liu X，Li G，Long Z，et al. Phase Ⅱ trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer [J]. J Surg Oncol，2017. DOI：10.1002/jso.24917.
[5] Satake H，Miki A，Kondo M，et al. Phase Ⅰ study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer（Neo G-SOX PI）[J]. ESMO Open，2017，2（1）：e000 130.
[6] Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes [J]. J Natl Compr Canc Netw，2009，7（1）：99-108.
[7] Shayne M，Culakova E，Poniewierski MS，et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy [J]. Cancer，2007，110（7）：1611-1620.
[8] Tandon P，Reddy KR，O'Leary JG，et al. A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis [J]. Hepatology，2017， 65（1）：217-224.
[9] Grimaldi S，Terroir M，Caramella C. Advances in oncological treatment：limitations of RECIST 1.1 criteria [J]. Q J Nucl Med Mol Imaging，2017.DOI：10.23736/S1824-4785.17.03-038-2.
[10] Beaver CC，Magnan MA. Managing Chemotherapy Side Effects：Achieving Reliable and Equitable Outcomes [J]. Clin J Oncol Nurs，2016，20（6）：589-591.
[11] Li Y，Chen J，He Q，et al. Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer：a propensity score analysis [J]. Oncotarget，2017，8（49）：86 886-86 896.
[12] Sun Y，Yang L，Wang C，et al. Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection [J]. Oncotarget，2017，8（43）：75 186-75 194.
[13] Schraa SJ，Frerichs KA，Agterof MJ，et al. Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice [J]. Eur J Cancer，2017，79：152-157.
[14] Tanday S. Weekly dose-dense chemotherapy for ovarian cancer [J]. Lancet Oncol，2016，17（4）：e138.
[15] Maura F，Guidetti A，Pellegrinelli A，et al. High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression [J]. Blood Cancer J，2017，7（3）：e544.
[16] Aoyama T，Nishikawa K，Fujitani K，et al. Early results of a randomized two-by-two factorial phase Ⅱ trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer [J]. Ann Oncol，2017，28（8）：1876-1881.
[17] Liguigli W，Tomasello G，Toppo L，et al. Safety and efficacy of dose-dense chemotherapy with TCF regimen in elderly patients with locally advanced or metastatic gastric cancer [J]. Tumori，2017，103（1）：93-100.
[18] Kodera Y，Ishiyama A，Yoshikawa T，et al. A feasibility study of postoperative chemotherapy with S-1 and cisplatin（CDDP）for gastric carcinoma（CCOG0703）[J]. Gastric Cancer，2010，13（3）：197-203.
[19] Takahari D，Hamaguchi T，Yoshimura K，et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer [J]. Cancer Chemother Pharmacol，2011，67（6）：1423-1428.
[20] Kitagawa M，Shimura T，Yamada T，et al. The relationship between antitumor effects and relative dose intensity of S-1 plus cisplatin treatment for metastatic gastric cancer [J]. Anticancer Res，2012，32（5）：1763-1768.
[21] Klute KA，Brouwer J，Jhawer M，et al. Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies：A multicentre analysis [J]. Eur J Cancer，2016，63（623）：189-200.
[22] Zhu C，Wang Y，Wang X，et al. Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens：epidemiological features，timing，predictors and clinical impacts [J]. J Cancer，2017，8（13）：2614-2625.
[23] Ychou M，Boige V，Pignon JP，et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma：an FNCLCC and FFCD multicenter phase Ⅲ trial [J]. J Clin Oncol，2011，29（13）：1715-1721.
[24] Kang YK，Boku N，Satoh T，et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to，or intolerant of，at least two previous chemotherapy regimens（ONO-4538-12，ATTRACTION-2）：a randomised，double-blind，placebo-controlled，phase 3 trial [J]. Lancet，2017，390（10111）：2461-2471.
[25] Apicella M，Corso S，Giordano S. Targeted therapies for gastric cancer： failures and hopes from clinical trials [J]. Oncotarget，2017，8（34）：57 654-57 669.
[26] Wagner AD，Syn NL，Moehler M，et al. Chemotherapy for advanced gastric cancer [J]. Cochrane Database Syst Rev，2017，8：CD004064. |
|
|
|
